Adverum Biotechnologies, Inc.
ADVM
$3.43
$0.103.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -72.22% | -100.00% | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -72.22% | -100.00% | -100.00% | -- | -- |
| Cost of Revenue | -17.71% | -20.34% | -23.11% | -18.73% | -15.97% |
| Gross Profit | 15.24% | 16.86% | 20.03% | 22.50% | 19.62% |
| SG&A Expenses | -25.18% | -22.31% | -7.65% | -9.21% | -16.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.44% | -21.07% | -17.57% | -15.26% | -16.10% |
| Operating Income | 18.97% | 18.94% | 15.48% | 17.66% | 18.41% |
| Income Before Tax | 24.48% | 24.28% | 21.72% | 23.45% | 19.24% |
| Income Tax Expenses | -1,631.08% | -1,608.11% | -1,620.83% | -1,556.76% | 34.55% |
| Earnings from Continuing Operations | 25.42% | 25.16% | 22.51% | 24.18% | 19.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.42% | 25.16% | 22.51% | 24.18% | 19.22% |
| EBIT | 18.97% | 18.94% | 15.48% | 17.66% | 18.41% |
| EBITDA | 17.90% | 18.23% | 15.03% | 17.85% | 19.31% |
| EPS Basic | 51.95% | 40.08% | 30.06% | 25.38% | 20.54% |
| Normalized Basic EPS | 49.26% | 37.12% | 25.97% | 21.34% | 22.62% |
| EPS Diluted | 51.95% | 40.08% | 30.06% | 25.38% | 20.54% |
| Normalized Diluted EPS | 49.26% | 37.12% | 25.97% | 21.34% | 22.62% |
| Average Basic Shares Outstanding | 69.97% | 43.71% | 17.33% | 1.58% | 1.69% |
| Average Diluted Shares Outstanding | 69.97% | 43.71% | 17.33% | 1.58% | 1.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
